Phase 2 COSMOS study results published in The Lancet demonstrate efficacy and safety of Janssen’s once-daily imeprevir

Results from the Phase 2 COSMOS (Combination OfSiMeprevir and sOfosbuvir in HCV genotype 1 infected patientS) clinical study were published July 28 in The Lancet, demonstrating that 92 percent of genotype 1 chronic hepatitis C virus (HCV) adult patients treated with Janssen R&D Ireland’s (Janssen) simeprevir, an NS3/4A protease inhibitor, in combination with sofosbuvir, achieved sustained virologic response 12 weeks after the end of treatment (SVR12), including those patients with compensated cirrhosis and prior null response to treatment with pegylated interferon (PegIFN) and ribavirin (RBV).

According to findings from the study, the all-oral 12-week, interferon-free treatment regimen with simeprevir and sofosbuvir resulted in consistent SVR12 rates regardless of degree of fibrosis, and was an effective and well-tolerated therapeutic regimen in both treatment-naïve and prior null-responder patients.

“The publication of results from the COSMOS study in The Lancet on World Hepatitis Day underscores the significance of these data to the hepatitis C community,” said Eric Lawitz, M.D., Principal Investigator of the COSMOS study, Medical Director at The Texas Liver Institute, and Professor of Medicine at University of Texas Health Science Center. “These data demonstrate that the all-oral, interferon-free combination of simeprevir and sofosbuvir offers a highly effective 12-week treatment option for patients, including prior null-responders and those with advanced fibrosis who are considered difficult to cure.”

The open-label, randomised Phase 2 COSMOS study investigated the efficacy and safety of 12 or 24 weeks of simeprevir (150 mg once daily) with sofosbuvir (400 mg once daily) without or with RBV in HCV genotype 1 chronically infected patients with compensated liver disease. The study included two cohorts: Cohort 1 included null-responder patients with no to moderate liver fibrosis (defined as METAVIR F0 to F2 scores) and Cohort 2 included treatment-naïve and prior null-responder patients with advanced fibrosis, including cirrhosis (defined as METAVIR F3 to F4 scores).¹

In Cohort 1 (N=80), 93 percent and 96 percent of genotype 1 HCV patients with no to moderate liver fibrosis who were prior null responders to PegIFN + RBV treated with simeprevir and sofosbuvir for 12 weeks without or with RBV, respectively, achieved SVR12. Additionally, in Cohort 2 (N=87), 93 percent of treatment-naïve and prior null-responder patients with genotype 1 HCV and advanced liver fibrosis treated with simeprevir and sofosbuvir for 12 weeks without or with RBV, respectively, achieved SVR12.¹

In the COSMOS trial, the most common (> 10 percent) adverse events reported during treatment with simeprevir in combination with sofosbuvir without and with RBV were fatigue (31 percent), headache (20 percent), and nausea (16 percent).

“The publication of the COSMOS study results represents the first peer-reviewed report describing the use of simeprevir in combination with other direct-acting antiviral agents in an all-oral interferon-free regimen,” said Gaston Picchio, Hepatitis Disease Area Leader, Janssen Research & Development. “This has been included as part of the European marketing authorisation earlier this year and we are further discussing these results with other authorities around the world to better inform the treatment of hepatitis C patients.”

Based on the findings from the COSMOS study, in April 2014, Janssen announced initiation of the Phase 3 OPTIMIST-1 and OPTIMIST-2 trials examining the safety and efficacy of simeprevir and sofosbuvir without interferon or RBV for the treatment of chronic genotype 1 HCV infection. For more information please visit www.clinicaltrials.gov.

Sofosbuvir is a nucleotide analog NS5B polymerase inhibitor developed by Gilead Sciences, Inc.

1. Lawitz E et al. Simeprevir plus sofosbuvir with/without ribavirin for treating chronic 1 HCV genotype 1 infection in prior null-responders to 2 peginterferon/ribavirin and treatment-naïve patients (COSMOS: a 3 randomised study). Lancet 2014, doi.org/10.1016/S0140-6736(14)61036-9,